NewLimit

NewLimit is a revolutionary biotechnology company founded in 2022, with the mission to extend human healthspan through the development of epigenetic reprogramming therapies. The company's slogan, "NewLimit is a biotechnology company working to extend human healthspan by developing epigenetic reprogramming therapies," encapsulates its core focus. NewLimit's approach involves developing medicines to address age-related diseases by reprogramming the epigenome, thereby restoring regenerative potential in aged and diseased cells. The company leverages functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease on an unprecedented scale. In May 16, 2023, NewLimit secured a significant $40.00M Series A investment from a consortium of prominent investors including Founders Fund, Kleiner Perkins, Elad Gil, Dimension, Garry Tan, Fred Ehrsam, and Eric Schmidt. This noteworthy investment not only validates the company's innovative approach but also provides the necessary financial resources to advance its groundbreaking research and development initiatives. Headquartered in the United States, NewLimit operates at the intersection of biotechnology and health care, positioning itself at the forefront of efforts to redefine the possibilities of human health and longevity.